6f4c: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='6f4c' size='340' side='right' caption='[[6f4c]], [[Resolution|resolution]] 2.80Å' scene=''> | <StructureSection load='6f4c' size='340' side='right' caption='[[6f4c]], [[Resolution|resolution]] 2.80Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[6f4c]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6F4C OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6F4C FirstGlance]. <br> | <table><tr><td colspan='2'>[[6f4c]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Nicbe Nicbe]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6F4C OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6F4C FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6f4c FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6f4c OCA], [http://pdbe.org/6f4c PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6f4c RCSB], [http://www.ebi.ac.uk/pdbsum/6f4c PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6f4c ProSAT]</span></td></tr> | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6f4c FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6f4c OCA], [http://pdbe.org/6f4c PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6f4c RCSB], [http://www.ebi.ac.uk/pdbsum/6f4c PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6f4c ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
alpha-Galactosidases (EC 3.2.1.22) are retaining glycosidases that cleave terminal alpha-linked galactose residues from glycoconjugate substrates. alpha-Galactosidases take part in the turnover of cell wall-associated galactomannans in plants and in the lysosomal degradation of glycosphingolipids in animals. Deficiency of human alpha-galactosidase A (alpha-Gal A) causes Fabry disease (FD), a heritable, X-linked lysosomal storage disorder, characterized by accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lysoGb3). Current management of FD involves enzyme-replacement therapy (ERT). An activity-based probe (ABP) covalently labeling the catalytic nucleophile of alpha-Gal A has been previously designed to study alpha-galactosidases for use in FD therapy. Here, we report that this ABP labels proteins in Nicotiana benthamiana leaf extracts, enabling the identification and biochemical characterization of an N. benthamiana alpha-galactosidase we name here A1.1 (gene accession GJZM-1660). The transiently overexpressed and purified enzyme was a monomer lacking N-glycans and was active toward 4-methylumbelliferyl-alpha-D-galactopyranoside substrate (Km = 0.17 mM) over a broad pH range. A1.1 structural analysis by X-ray crystallography revealed marked similarities with human alpha-Gal A, even including A1.1's ability to hydrolyze Gb3 and lysoGb3, which are not endogenous in plants. Of note, A1.1 uptake into FD fibroblasts reduced the elevated lysoGb3 levels in these cells, consistent with A1.1 delivery to lysosomes as revealed by confocal microscopy. The ease of production and the features of A1.1, such as stability over a broad pH range, combined with its capacity to degrade glycosphingolipid substrates, warrant further examination of its value as a potential therapeutic agent for ERT-based FD management. | |||
Nicotiana benthamiana alpha-galactosidase A1.1 can functionally complement human alpha-galactosidase A deficiency associated with Fabry disease.,Kytidou K, Beekwilder J, Artola M, van Meel E, Wilbers RHP, Moolenaar GF, Goosen N, Ferraz MJ, Katzy R, Voskamp P, Florea BI, Hokke CH, Overkleeft HS, Schots A, Bosch D, Pannu N, Aerts JMFG J Biol Chem. 2018 Apr 19. pii: RA118.001774. doi: 10.1074/jbc.RA118.001774. PMID:29674318<ref>PMID:29674318</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 6f4c" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Nicbe]] | |||
[[Category: Aerts, J M.F G]] | [[Category: Aerts, J M.F G]] | ||
[[Category: Kytidou, K]] | [[Category: Kytidou, K]] | ||